Drug costs can rise fast, yet many employers still can’t see where the money goes. That is the core PBM problem in 2026: visibility.

TL;DR: A pharmacy benefit manager, or PBM, helps employers manage prescription drug benefits through price negotiation, Formulary design, pharmacy networks, and claims processing. PBMs can lower costs, but only when contract terms, reporting, and oversight line up with the employer’s goals.

Key takeaways

• PBMs can reduce unit cost and improve pharmacy operations, but hidden fees can wipe out those gains.
• Large rebates do not always mean lower Net Cost.
• New federal PBM reforms in 2026 raised the bar for reporting, Rebate pass-through, and annual audit rights over time.
• C-suite, finance, and HR leaders need simple data they can act on, not dense reports no one uses.

JA’s view is simple: data should help people make better decisions. That is why clear pharmacy plan benchmarking data matters. It turns pharmacy spend into knowledge you can use, not noise you have to sort through later.

How PBMs help control drug costs, and where hidden costs can show up #

A PBM is the middle operator of a prescription drug plan. It works between the employer, the health plan, pharmacies, and drug makers. In a good setup, the PBM uses scale to negotiate pricing, manage drug lists, process claims, and support safe use.

That can help. Employers often get lower unit prices, broader pharmacy access, and less day-to-day admin burden. Finance teams also get a better shot at trend control when data is timely.

Still, the money trail can get murky. Some PBMs profit through Spread Pricing, retained rebates, hidden admin charges, or terms tied to affiliated pharmacies. Formulary decisions can also tilt toward higher Rebate drugs, even when another option has a lower Net Cost for the plan.

That is why PBM oversight starts with understanding the moving parts before judging the model.

The main jobs a PBM handles behind the scenes #

PBMs do more than process drug claims. They also shape how members use the plan.

They negotiate rebates with drug makers. Those rebates may lower employer cost, reduce member cost, or stay with the PBM, depending on the contract. They build formularies, which are the drug lists your plan prefers and covers. A drug may land on a better tier because it is low cost, clinically sound, or highly rebated.

PBMs also manage prior authorization, Step Therapy, and Quantity Limits. Those rules can curb waste, but they can also frustrate members if the process is slow or unclear. In addition, PBMs create pharmacy networks and set terms for retail, mail, specialty, and home delivery channels.

Specialty drugs need special attention. In 2026, they often drive more than 60% of employer pharmacy spend while making up under 5% of scripts. That is why specialty management, site of care rules, and biosimilar strategy matter so much.

The cost drivers employers should never ignore #

The first trap is Spread Pricing. That happens when the PBM bills the employer one amount, pays the pharmacy less, and keeps the spread.

The second is Rebate retention. A contract may promise strong Rebate performance, yet the employer may not receive the full amount. Even worse, high rebates can hide a worse net price.

A large Rebate can make a report look strong while the plan still pays too much overall.

Specialty trend is another major driver. GLP-1 drugs, oncology therapies, and gene or cell therapies can move a plan’s pharmacy spend in a hurry. Channel mix also matters. A claim filled at retail, mail, or specialty can carry very different costs.

Then come the quieter charges. Admin fees, data fees, clinical program fees, audit limits, and subcontractor revenue can pile up. Therefore, employers should focus on total Net Cost, not headline discount numbers.

The real pros and cons of using PBMs for transparent drug cost control #

PBMs can create real value. They also create risk when incentives are misaligned. The difference often comes down to contract clarity, usable reporting, and steady oversight.

This is not only a budget issue. Pharmacy strategy shapes member access, Adherence, and trust. If an employee cannot get a needed drug, the plan feels broken, even if finance sees a savings line on paper.

Where a well structured PBM relationship can create savings #

A sound PBM model can lower unit cost through stronger purchasing power and tighter pharmacy terms. It can also lift generic fill rates, improve biosimilar adoption, and guide high-cost drugs to the right clinical review.

When reporting is clear, leaders can forecast trend better. That helps with budgeting, renewal planning, and reserve decisions. HR teams benefit too, because fewer claim surprises usually mean fewer member complaints.

Some transparent pricing models also improve alignment. The PBM earns an agreed admin fee, while the employer gets cleaner access to claims, rebates, and fee detail. In some cases, employers see meaningful year-one savings. Still, savings vary by Plan Design, drug mix, member needs, and current contract quality.

Better pharmacy strategy can also create stronger ROR, or Return on Relationship. Employees judge the benefit by how it works for their family at the pharmacy counter, not by a Rebate line buried in a report.

Where PBM arrangements can go wrong #

Trouble starts with opaque contracts. Vague terms around “rebates,” “discounts,” “guarantees,” or “specialty” leave room for lost value.

Reporting can also fail the employer. A thick report with dozens of tabs may look detailed, yet still hide Net Cost. If finance cannot trace gross cost, rebates, admin fees, and retained revenue in one clear view, oversight is weak.

Member disruption is another risk. A network change, Formulary shift, or prior auth rule can create confusion fast. That affects Adherence and trust, especially for people managing cancer, diabetes, infertility, or rare disease.

Narrow networks can save money, but they may also reduce access. Some vendors also make up lost Rebate revenue through higher fees elsewhere. Therefore, transparency alone does not solve the problem. Employers still need strong language, frequent review, and data they can verify.

What to ask before you sign, renew, or expand a PBM contract #

Strong pharmacy strategy follows a disciplined process. First, listen to the pain points. Next, assess the current contract and reporting. Then develop a clear set of terms, communicate expectations, and execute with accountability.

That approach matters more now because 2026 federal reforms raised employer expectations around PBM disclosure. Early 2026 legislation increased pressure around reporting, annual audit rights, and full Rebate pass-through over time, with major changes phasing in for later plan years. A separate DOL rulemaking effort also pushed Self-Funded plans toward earlier compensation disclosure.

For employers tracking those changes, JA’s new legislation on pharmacy compliance is a helpful reference point.

Do ask for full pass through pricing, audit rights, and clean data access #

Ask for 100% Rebate pass-through in plain contract language. Ban Spread Pricing unless a different model is fully disclosed and approved. Define every admin fee, clinical fee, and subcontractor payment.

Request annual audit rights with an auditor you choose. That right should cover rebates, pharmacy reimbursement, specialty claims, and affiliated entities. Also require access to full claims data in a usable format, not only summary reports.

Employers should also ask for a simple gross-to-net view. You should be able to trace drug spend from ingredient cost to Dispensing Fee, member cost share, rebates, and final net plan cost. In addition, ask how the PBM will support upcoming reporting expectations, including more frequent reporting and future Plan Year changes tied to recent federal reform.

Do measure success with Net Cost, member impact, and trend control #

The cleanest scorecard starts with Net Cost per script and Net Cost trend. After that, track specialty spend, generic fill rate, biosimilar use, top drug classes, and the share of spend tied to a small number of claimants.

Member impact belongs on the same dashboard. Watch disruption rates, prior auth turnaround, appeal volume, pharmacy access, and abandonment on high-cost drugs. If employees cannot use the benefit, the plan is underperforming.

Regular review meetings matter. Quarterly discussions often work best because pharmacy trend moves fast. Benchmarking also helps. A plan may look fine year over year and still be lagging peers on specialty management or channel mix.

Do not chase big rebates or sign away visibility #

Rebate guarantees alone can mislead buyers. A PBM can hit a Rebate target and still cost the employer more overall.

Read definitions with care. Broad confidentiality terms, loose audit language, missing affiliate disclosure, and vague references to “custom” pricing are red flags. The same goes for reports that are hard to read or impossible to reconcile to invoices.

Watch for pricing terms that block oversight. If the contract limits data access, narrows audit scope, or lets the PBM change Formulary strategy without clear notice, the employer carries too much risk.

A smarter employer playbook for pharmacy strategy in 2026 and beyond #

The best pharmacy strategy supports cost control and employee well-being at the same time. It also treats PBM review as an ongoing business discipline, not a once-every-few-years procurement task.

That matters even more as specialty spend keeps climbing. JA has long pointed out the specialty drug spending impact on employer plans, and that pressure is only stronger now.

Build a pharmacy strategy that is clear, proactive, and easy to explain #

Start with the current contract. Map every revenue stream, every fee, and every point where the PBM can retain value. Then benchmark plan performance and identify the top drug cost drivers by class, site, and channel.

Bring finance and HR together early. Finance needs cost clarity. HR needs to protect access and member experience. When those teams work from the same data, decisions improve.

Communicate changes in plain language. Employees use benefits better when they understand them, and trust grows when the plan explains why a change is happening.

When it may be time to rethink your current PBM model #

A review is wise when specialty costs keep rising without a clear plan. The same is true when reports show gross spend but hide Net Cost, or when the vendor resists audit support and full disclosure.

Frequent member complaints are another signal. So is pushback on pass-through pricing, affiliate disclosure, or data access. At that point, the issue is not only price. It is governance.

PBMs can help control drug costs. Employers get the full value only when they have contract clarity, usable data, and steady oversight.

Executive teams should keep their focus on transparency, measurable outcomes, and member impact. Savings promises are easy to make. Clear reporting, strong terms, and a better pharmacy experience are what count.

Using PBMs for Transparent Drug Cost Control #

Drug costs can rise fast, yet many employers still can’t see where the money goes. That is the core PBM problem in 2026: visibility.

TL;DR: A pharmacy benefit manager, or PBM, helps employers manage prescription drug benefits through price negotiation, Formulary design, pharmacy networks, and claims processing. PBMs can lower costs, but only when contract terms, reporting, and oversight line up with the employer’s goals.

Key takeaways

• PBMs can reduce unit cost and improve pharmacy operations, but hidden fees can wipe out those gains.
• Large rebates do not always mean lower Net Cost.
• New federal PBM reforms in 2026 raised the bar for reporting, Rebate pass-through, and annual audit rights over time.
• C-suite, finance, and HR leaders need simple data they can act on, not dense reports no one uses.

JA’s view is simple: data should help people make better decisions. That is why clear pharmacy plan benchmarking data matters. It turns pharmacy spend into knowledge you can use, not noise you have to sort through later.

How PBMs help control drug costs, and where hidden costs can show up #

A PBM is the middle operator of a prescription drug plan. It works between the employer, the health plan, pharmacies, and drug makers. In a good setup, the PBM uses scale to negotiate pricing, manage drug lists, process claims, and support safe use.

That can help. Employers often get lower unit prices, broader pharmacy access, and less day-to-day admin burden. Finance teams also get a better shot at trend control when data is timely.

Still, the money trail can get murky. Some PBMs profit through Spread Pricing, retained rebates, hidden admin charges, or terms tied to affiliated pharmacies. Formulary decisions can also tilt toward higher Rebate drugs, even when another option has a lower Net Cost for the plan.

That is why PBM oversight starts with understanding the moving parts before judging the model.

The main jobs a PBM handles behind the scenes #

PBMs do more than process drug claims. They also shape how members use the plan.

They negotiate rebates with drug makers. Those rebates may lower employer cost, reduce member cost, or stay with the PBM, depending on the contract. They build formularies, which are the drug lists your plan prefers and covers. A drug may land on a better tier because it is low cost, clinically sound, or highly rebated.

PBMs also manage prior authorization, Step Therapy, and Quantity Limits. Those rules can curb waste, but they can also frustrate members if the process is slow or unclear. In addition, PBMs create pharmacy networks and set terms for retail, mail, specialty, and home delivery channels.

Specialty drugs need special attention. In 2026, they often drive more than 60% of employer pharmacy spend while making up under 5% of scripts. That is why specialty management, site of care rules, and biosimilar strategy matter so much.

The cost drivers employers should never ignore #

The first trap is Spread Pricing. That happens when the PBM bills the employer one amount, pays the pharmacy less, and keeps the spread.

The second is Rebate retention. A contract may promise strong Rebate performance, yet the employer may not receive the full amount. Even worse, high rebates can hide a worse net price.

A large Rebate can make a report look strong while the plan still pays too much overall.

Specialty trend is another major driver. GLP-1 drugs, oncology therapies, and gene or cell therapies can move a plan’s pharmacy spend in a hurry. Channel mix also matters. A claim filled at retail, mail, or specialty can carry very different costs.

Then come the quieter charges. Admin fees, data fees, clinical program fees, audit limits, and subcontractor revenue can pile up. Therefore, employers should focus on total Net Cost, not headline discount numbers.

The real pros and cons of using PBMs for transparent drug cost control #

PBMs can create real value. They also create risk when incentives are misaligned. The difference often comes down to contract clarity, usable reporting, and steady oversight.

This is not only a budget issue. Pharmacy strategy shapes member access, Adherence, and trust. If an employee cannot get a needed drug, the plan feels broken, even if finance sees a savings line on paper.

Where a well structured PBM relationship can create savings #

A sound PBM model can lower unit cost through stronger purchasing power and tighter pharmacy terms. It can also lift generic fill rates, improve biosimilar adoption, and guide high-cost drugs to the right clinical review.

When reporting is clear, leaders can forecast trend better. That helps with budgeting, renewal planning, and reserve decisions. HR teams benefit too, because fewer claim surprises usually mean fewer member complaints.

Some transparent pricing models also improve alignment. The PBM earns an agreed admin fee, while the employer gets cleaner access to claims, rebates, and fee detail. In some cases, employers see meaningful year-one savings. Still, savings vary by Plan Design, drug mix, member needs, and current contract quality.

Better pharmacy strategy can also create stronger ROR, or Return on Relationship. Employees judge the benefit by how it works for their family at the pharmacy counter, not by a Rebate line buried in a report.

Where PBM arrangements can go wrong #

Trouble starts with opaque contracts. Vague terms around “rebates,” “discounts,” “guarantees,” or “specialty” leave room for lost value.

Reporting can also fail the employer. A thick report with dozens of tabs may look detailed, yet still hide Net Cost. If finance cannot trace gross cost, rebates, admin fees, and retained revenue in one clear view, oversight is weak.

Member disruption is another risk. A network change, Formulary shift, or prior auth rule can create confusion fast. That affects Adherence and trust, especially for people managing cancer, diabetes, infertility, or rare disease.

Narrow networks can save money, but they may also reduce access. Some vendors also make up lost Rebate revenue through higher fees elsewhere. Therefore, transparency alone does not solve the problem. Employers still need strong language, frequent review, and data they can verify.

What to ask before you sign, renew, or expand a PBM contract #

Strong pharmacy strategy follows a disciplined process. First, listen to the pain points. Next, assess the current contract and reporting. Then develop a clear set of terms, communicate expectations, and execute with accountability.

That approach matters more now because 2026 federal reforms raised employer expectations around PBM disclosure. Early 2026 legislation increased pressure around reporting, annual audit rights, and full Rebate pass-through over time, with major changes phasing in for later plan years. A separate DOL rulemaking effort also pushed Self-Funded plans toward earlier compensation disclosure.

For employers tracking those changes, JA’s new legislation on pharmacy compliance is a helpful reference point.

Do ask for full pass through pricing, audit rights, and clean data access #

Ask for 100% Rebate pass-through in plain contract language. Ban Spread Pricing unless a different model is fully disclosed and approved. Define every admin fee, clinical fee, and subcontractor payment.

Request annual audit rights with an auditor you choose. That right should cover rebates, pharmacy reimbursement, specialty claims, and affiliated entities. Also require access to full claims data in a usable format, not only summary reports.

Employers should also ask for a simple gross-to-net view. You should be able to trace drug spend from ingredient cost to Dispensing Fee, member cost share, rebates, and final net plan cost. In addition, ask how the PBM will support upcoming reporting expectations, including more frequent reporting and future Plan Year changes tied to recent federal reform.

Do measure success with Net Cost, member impact, and trend control #

The cleanest scorecard starts with Net Cost per script and Net Cost trend. After that, track specialty spend, generic fill rate, biosimilar use, top drug classes, and the share of spend tied to a small number of claimants.

Member impact belongs on the same dashboard. Watch disruption rates, prior auth turnaround, appeal volume, pharmacy access, and abandonment on high-cost drugs. If employees cannot use the benefit, the plan is underperforming.

Regular review meetings matter. Quarterly discussions often work best because pharmacy trend moves fast. Benchmarking also helps. A plan may look fine year over year and still be lagging peers on specialty management or channel mix.

Do not chase big rebates or sign away visibility #

Rebate guarantees alone can mislead buyers. A PBM can hit a Rebate target and still cost the employer more overall.

Read definitions with care. Broad confidentiality terms, loose audit language, missing affiliate disclosure, and vague references to “custom” pricing are red flags. The same goes for reports that are hard to read or impossible to reconcile to invoices.

Watch for pricing terms that block oversight. If the contract limits data access, narrows audit scope, or lets the PBM change Formulary strategy without clear notice, the employer carries too much risk.

A smarter employer playbook for pharmacy strategy in 2026 and beyond #

The best pharmacy strategy supports cost control and employee well-being at the same time. It also treats PBM review as an ongoing business discipline, not a once-every-few-years procurement task.

That matters even more as specialty spend keeps climbing. JA has long pointed out the specialty drug spending impact on employer plans, and that pressure is only stronger now.

Build a pharmacy strategy that is clear, proactive, and easy to explain #

Start with the current contract. Map every revenue stream, every fee, and every point where the PBM can retain value. Then benchmark plan performance and identify the top drug cost drivers by class, site, and channel.

Bring finance and HR together early. Finance needs cost clarity. HR needs to protect access and member experience. When those teams work from the same data, decisions improve.

Communicate changes in plain language. Employees use benefits better when they understand them, and trust grows when the plan explains why a change is happening.

When it may be time to rethink your current PBM model #

A review is wise when specialty costs keep rising without a clear plan. The same is true when reports show gross spend but hide Net Cost, or when the vendor resists audit support and full disclosure.

Frequent member complaints are another signal. So is pushback on pass-through pricing, affiliate disclosure, or data access. At that point, the issue is not only price. It is governance.

PBMs can help control drug costs. Employers get the full value only when they have contract clarity, usable data, and steady oversight.

Executive teams should keep their focus on transparency, measurable outcomes, and member impact. Savings promises are easy to make. Clear reporting, strong terms, and a better pharmacy experience are what count.